Research Study Summary
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Crenezumab in patients with prodromal to mild Alzheimer's Disease.
Alzheimer’s disease (AD) is the most common cause of dementia. The deposition of extracellular amyloid plaques in the brain is a hallmark pathological
finding in AD. These amyloid plaques are primarily composed of Aβ peptides. This study is to evaluate crenezumab, a monoclonal antibody, that has been shown to inhibit self-association and aggregation of Aβ peptides.
To Learn more
CW ID: 216051
Date Last Changed:
June 14, 2016
Clinical Trial Snapshot
- Both Male and Female
- 50 to 85 Years
- Overall Status
- 100 Weeks
- Facility Type
- Weight between 40 and 120 kg, inclusive
- Patient meets NIAAA core clinical criteria for probable AD dementia or prodromal AD
- Evidence of the AD pathological process, by a positive amyloid assessment either on CSF Aβ1−42 levels as measured on the Elecsys β-Amyloid(1-42) Test System OR
amyloid PET scan by qualitative read by the core/central PET laboratory.
- Demonstrated abnormal memory function at screening
- Evidence of retrospective decline .
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.